| |
Continue drug, continue pregnancy (%)
|
Stop drug, continue pregnancy (%)
|
Continue drug, counsel regarding termination (%)
|
Stop drug, counsel regarding termination (%)
|
Not sure (%)
|
|---|
|
Conventional synthetic disease modifying anti-rheumatic drugs
|
|
Azathioprine
|
80.3*
|
6.1
|
1.5
|
4.5
|
7.6
|
|
Chloroquine
|
71.2
|
7.6
|
3.0
|
0
|
18.2
|
|
Cyclophosphamide
|
0
|
16.7
|
13.6
|
60.6
|
9.1
|
|
Cyclosporine
|
27.3
|
18.2
|
1.5
|
19.7
|
33.3
|
|
Doxycycline
|
0
|
29.2
|
0
|
6.2
|
64.6
|
|
Gold salts
|
30.3
|
18.2
|
0
|
9.1
|
42.4
|
|
Hydroxychloroquine
|
90.9*
|
4.5
|
1.5
|
0
|
3.0
|
|
Leflunomide
|
0
|
16.7
|
6.1
|
69.7
|
7.6
|
|
Methotrexate
|
0
|
22.7
|
7.6
|
65.2
|
4.5
|
|
Minocycline
|
0
|
34.8
|
0
|
6.1
|
69.7
|
|
Mycophenolate mofetil
|
3.0
|
19.7
|
10.6
|
47.0
|
19.7
|
|
Sulfasalazine
|
76.6*
|
14.1
|
0
|
1.6
|
7.8
|
|
Biologics/small molecules
|
|
Abatacept
|
24.2
|
45.5
|
1.5
|
6.1
|
22.7
|
|
Adalimumab
|
66.7
|
25.8
|
1.5
|
1.5
|
4.5
|
|
Anakinra
|
15.2
|
39.4
|
1.5
|
4.5
|
39.4
|
|
Apremilast
|
4.6
|
35.4
|
0
|
6.2
|
53.8
|
|
Certolizumab
|
63.1
|
26.2
|
1.5
|
0
|
9.2
|
|
Etanercept
|
69.7
|
24.2
|
0
|
1.5
|
4.5
|
|
Golimumab
|
60.6
|
28.8
|
1.5
|
1.5
|
7.6
|
|
Infliximab
|
60.0
|
29.2
|
1.5
|
1.5
|
7.7
|
|
Rituximab
|
18.2
|
39.4
|
1.5
|
6.1
|
34.8
|
|
Tocilizumab
|
18.2
|
39.4
|
1.5
|
4.5
|
36.4
|
|
Tofacitinib
|
3.0
|
31.8
|
0
|
7.6
|
57.6
|
|
Ustekinumab
|
13.8
|
33.8
|
1.5
|
4.6
|
46.2
|
|
Other medications
|
|
Celecoxib
|
39
|
56
|
0
|
0
|
3
|
|
Ibuprofen
|
64
|
33
|
0
|
0
|
3
|
|
Naproxen
|
65
|
32
|
0
|
0
|
3
|
|
Prednisone
|
85*
|
12
|
0
|
0
|
3
|
- *Indicates consensus among respondents based on a priori cut-off of ≥75%
